Literature DB >> 6422112

Pharmacological modulation of IgE-dependent mast cell degranulation in experimental autoimmune uveoretinitis.

Y de Kozak, J Sakai, J Sainte-Laudy, J P Faure, J Benveniste.   

Abstract

Immediate hypersensitivity phenomena have been shown previously to occur at the beginning of experimental autoimmune uveoretinitis (EAU) induced in Lewis rats by immunization with purified S-antigen from bovine retina. The onset time and severity of the disease were modified by modulating the mast cell (MC) function. Drugs blocking the release of mediators from MC, disodium cromoglycate and ketotifen, given as eyedrops, slightly delayed the onset and decreased the severity of inflammation. Compound 48/80, a drug effective in depleting MC of their inflammatory mediators, delayed significantly the onset, decreased and sometimes suppressed EAU, when given by the subconjunctival or intraperitoneal routes. No modification of the IgG and the IgE circulating anti-S-antibody level was demonstrated in both types of treatment, whereas in vitro reagin-dependent degranulation of peritoneal MC in the presence of the antigen was decreased in both cases. Identification of MC-bound reagins as IgE was strongly suggested by the blocking effect of anti-IgE antibodies on MC degranulation. These data confirm the link between MC activation and the onset and severity of EAU.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6422112

Source DB:  PubMed          Journal:  Jpn J Ophthalmol        ISSN: 0021-5155            Impact factor:   2.447


  3 in total

Review 1.  Ocular mast cells. Characterization in normal and disease states.

Authors:  E B Cook; J L Stahl; N P Barney; F M Graziano
Journal:  Clin Rev Allergy Immunol       Date:  2001-04       Impact factor: 8.667

2.  Prevention of experimental autoimmune uveoretinitis and experimental autoimmune pinealitis in (Lewis x Brown-Norway) F1 rats by HgCl2 injections.

Authors:  A Saoudi; B Bellon; Y de Kozak; J Kuhn; M C Vial; B Thillaye; P Druet
Journal:  Immunology       Date:  1991-10       Impact factor: 7.397

3.  Calming Down Mast Cells with Ketotifen: A Potential Strategy for Multiple Sclerosis Therapy?

Authors:  Karen Henriette Pinke; Sofia Fernanda Gonçalves Zorzella-Pezavento; Thais Fernanda de Campos Fraga-Silva; Luiza Ayumi Nishiyama Mimura; Larissa Ragozo Cardoso de Oliveira; Larissa Lumi Watanabe Ishikawa; Ana Angélica Henrique Fernandes; Vanessa Soares Lara; Alexandrina Sartori
Journal:  Neurotherapeutics       Date:  2020-01       Impact factor: 7.620

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.